S'abonner

Eosinophil extracellular trap cell death–derived DNA traps: Their presence in secretions and functional attributes - 10/06/15

Doi : 10.1016/j.jaci.2015.04.041 
Shigeharu Ueki, MD, PhD a, b, , Yasunori Konno, DDS a, Masahide Takeda, MD, PhD a, Yuki Moritoki, MD, PhD a, Makoto Hirokawa, MD, PhD a, Yoshinori Matsuwaki, MD, PhD c, Kohei Honda, MD, PhD d, Nobuo Ohta, MD, PhD e, Shiori Yamamoto, BSA f, Yuri Takagi f, Atsushi Wada, PhD f, Peter F. Weller, MD b
a Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan 
d Department of Otorhinolaryngology, Head and Neck Surgery, Akita University Graduate School of Medicine, Akita, Japan 
b Divisions of Allergy and Inflammation and Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 
c Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan 
e Department of Otorhinolaryngology, Yamagata University School of Medicine, Yamagata, Japan 
f Cell Analysis Center, Scientific Affairs, Sysmex Corporation, Kobe, Japan 

Corresponding author: Shigeharu Ueki, MD, PhD, Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita 010-8543, Japan.
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Wednesday 10 June 2015
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Background

Activated human eosinophils, as well as neutrophils, can release extracellular chromatin to form DNA traps through cytolytic extracellular trap cell death (ETosis). Although formations of neutrophil DNA traps are recognized in patients with various inflammatory conditions, neither the presence of ETosis-derived eosinophil DNA traps in human allergic diseases nor the characteristics of these DNA traps have been studied.

Objective

We investigated the presence of ETosis-derived DNA traps in eosinophil-rich sinus and ear secretions and the functional attributes of ETosis DNA traps.

Methods

Eosinophil-rich secretions obtained from patients with eosinophilic chronic rhinosinusitis and eosinophilic otitis media were studied microscopically. In vitro studies of ETosis and DNA trap formation used blood-derived eosinophils and neutrophils, and studies of the binding capacities of DNA traps used labeled bacteria and fluorescent microbeads. Stabilities of DNA traps were evaluated by using fluorescence microscopy.

Results

Abundant nuclear histone H1–bearing DNA traps formed in vivo in the eosinophilic secretions and contributed to their increased viscosity. In vitro, after brief shear flow, eosinophil ETosis-elicited DNA traps assembled to form stable aggregates. Eosinophil DNA traps entrapped bacteria and fungi and, through hydrophobic interactions, microbeads. In comparison with neutrophil-derived DNA traps, eosinophil DNA traps ultrastructurally exhibited thicker fibers with globular structures and were less susceptible to leukocyte-derived proteolytic degradation, likely because of the lesser protease activities of eosinophils.

Conclusions

In human allergic diseases local cytolysis of eosinophils not only releases free eosinophil granules but also generates nuclear-derived DNA traps that are major extracellular structural components within eosinophil-rich secretions.

Le texte complet de cet article est disponible en PDF.

Key words : Eosinophilic chronic rhinosinusitis, eosinophils, extracellular trap cell death, extracellular DNA traps, neutrophils

Abbreviations used : ECRS, EETosis, EOM, ETosis, NETosis, PMA, RT


Plan


 Supported in part by Uehara Memorial Foundation and Grant-in-Aid for Scientific Research13383320 (to S.U.), 25462675 (to N.O.), NIHR37-AI020241 (to P.F.W.), and R01-AI051645 (to P.F.W.).
 Disclosure of potential conflict of interest: S. Ueki has received research support from Grant-in-Aid for Scientific Research (no. 13383320) and the Uehara Memorial Foundation. M. Takeda has received research support from Grant-in-Aid for Scientific Research. Y. Moritoki has consultant arrangements with the Institute of Immunology, has received research support from Bristol Meyers Squibb, and has received payment for lectures from Chugai Pharmaceutical, and Takeda Pharmaceutical Company Limited. N. Ohta has received research support from Grant-in-Aid for Scientific Research (no. 25462675). S. Yamamoto, Y. Takagi, and A. Wada have received travel support from and are employed by Sysmex Corporation. P. F. Weller has received research support from the National Institutes of Health.


© 2015  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.